CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma

Boosting antitumor immunity has emerged as a powerful strategy in cancer treatment. While releasing T‐cell brakes has received most attention, tumor recognition by T cells is a pre‐requisite. Radiotherapy and certain cytotoxic drugs induce the release of damage‐associated molecular patterns, which promote tumor antigen cross‐presentation and T‐cell priming. Antibodies against the “do not eat me” signal CD47 cause macrophage phagocytosis of live tumor cells and drive the emergence of antitumor T cells. Here we show that CXCR4 activation, so far associated only with tumor progression and metastasis, also flags tumor cells to immune recognition. Both CXCL12, the natural CXCR4 ligand, and BoxA, a fragment of HMGB1, promote the release of DAMPs and the internalization of CD47, leading to protective antitumor immunity. We designate as Immunogenic Surrender the process by which CXCR4 turns in tumor cells to macrophages, thereby subjecting a rapidly growing tissue to immunological scrutiny. Importantly, while CXCL12 promotes tumor cell proliferation, BoxA reduces it, and might be exploited for the treatment of malignant mesothelioma and a variety of other tumors.

[1]  M. Bianchi,et al.  The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration , 2020, Frontiers in Immunology.

[2]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[3]  Brian F. Volkman,et al.  Biased antagonism of CXCR4 avoids antagonist tolerance , 2018, Science Signaling.

[4]  K. Tracey,et al.  Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance , 2018, Molecular Medicine.

[5]  L. Zitvogel,et al.  eIF2α phosphorylation is pathognomonic for immunogenic cell death , 2018, Cell Death & Differentiation.

[6]  M. Bianchi,et al.  High mobility group box 1 orchestrates tissue regeneration via CXCR4 , 2018, The Journal of experimental medicine.

[7]  M. Bianchi,et al.  High‐mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair , 2017, Immunological reviews.

[8]  M. Bianchi,et al.  HMGB1 as biomarker and drug target. , 2016, Pharmacological research.

[9]  A. Berns,et al.  Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells , 2016, Scientific Reports.

[10]  Wei Zhang,et al.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks , 2016, Oncogene.

[11]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[12]  S. Pastorino,et al.  Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression , 2015, Cell Death and Disease.

[13]  J. Violin,et al.  Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.

[14]  T. K. van den Berg,et al.  The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. , 2014, Annual review of immunology.

[15]  J. Aerts,et al.  Tumor-associated macrophages in thoracic malignancies. , 2013, Lung cancer.

[16]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[17]  H. Pass,et al.  Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. , 2012, Cancer research.

[18]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[19]  Ash A. Alizadeh,et al.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. , 2011, Cancer research.

[20]  L. You,et al.  The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma , 2011, The Journal of pathology.

[21]  Ash A. Alizadeh,et al.  Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.

[22]  H. Pass,et al.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.

[23]  Beverly A. Teicher,et al.  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.

[24]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[25]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[26]  P. van Endert,et al.  Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.

[27]  J. Wilson,et al.  Identification of the murine firefly luciferase-specific CD8 T-cell epitopes , 2009, Gene Therapy.

[28]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[29]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[30]  S. Müller,et al.  HMGB1 is an endogenous immune adjuvant released by necrotic cells , 2004, EMBO reports.

[31]  E. Ingulli,et al.  Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells , 2001, The Journal of experimental medicine.

[32]  R. China,et al.  The CD 47-signal regulatory protein alpha ( SIRPa ) interaction is a therapeutic target for human solid tumors , 2012 .